Review Open Access
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 7, 2007; 13(13): 1897-1905
Published online Apr 7, 2007. doi: 10.3748/wjg.v13.i13.1897
Treatment of hepatitis C virus infection
Kilian Weigand, Wolfgang Stremmel, Jens Encke, University of Heidelberg, Department of Gastroenterology and Hepatology, Im Neuenheimer Feld 410, Heidelberg 69120, Germany
Author contributions: All authors contributed equally to the work.
Correspondence to: Professor J Encke, University of Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, Hei-delberg D-69120, Germany. jens_encke@med.uni-heidelberg.de
Telephone: +49-6221-5638825 Fax: +49-6221-566858
Received: January 11, 2007
Revised: February 3, 2006
Accepted: March 14, 2007
Published online: April 7, 2007

Abstract

Acute and chronic hepatitis C virus (HCV) infection remains a serious health problem worldwide, however, there has been advancement in the treatment of HCV infection due to standard treatment using pegylated interferon and ribavirin. The literature indicates that therapy for HCV is becoming more individualized. In addition to considering genotype and viral RNA levels before treatment, achievement of an early virologic response (EVR) and a rapid virologic response (RVR) is now possible during therapy. Moreover, problem patients, such as non-responders, relapsers, HIV or HBV co-infected patients, patients with liver cirrhosis, and pre- or post-liver transplantation patients are an increasing fraction of the patients requiring treatment. This article reviews the literature regarding standard treatments and problem patients with acute and chronic HCV infection. It also includes discussion on contraindications and side effects of treatment with interferon and ribavirin, as well as new drug development.

Key Words: Hepatitis C virus; Acute and chronic HCV infection; Treatment; Pegylated interferon; Ribavirin; Sustained virologic response; Non-responders; Relapsers



INTRODUCTION

Infection with hepatitis C virus (HCV) remains a severe life-threatening medical and public health problem worldwide. Every year there are an estimated 3 to 4 million new cases of infection due to transfusion contamination, contaminated injection needles, and parenteral exposure[1-5]. There is a lower rate of infection for sexual transmission[6]. About 55%-85% of individuals with acute HCV infection become chronically infected and are at risk for developing hepatocellular injury, liver cirrhosis, hepatocellular carcinoma or liver failure[7-9].

In total, More than 170 million individuals (> 2% of the world’s population) are infected with HCV[10]. While prevention of primary infection is possible, vertical transmission of HCV remains a significant problem especially in developing countries.

The transition from acute to chronic infection is only partly understood. However, early treatment with pegylated interferon (PEG-IFN) alpha to prevent chronic infection is effective in up to 95% of patients with acute hepatitis[11-13]. Determining the optimal treatment for chronically infected individuals is a remaining question. To date, standard treatment for chronically infected patients is the combination of PEG-IFN alpha with ribavirin[14]. Recent studies have demonstrated that a relatively high number of patients acquire sustained virologic response (SVR), defined as non-detectable serum virus RNA levels by qualitative PCR 6 mo after end of treatment[15,16], and this is the primary goal of therapy. However, a large number of patients remain viraemic and chronically infected. In addition, many patients suffer from severe side effects while receiving this combination therapy[14-17]. These are the reasons for attempts to find medications with higher SVRs, better tolerability and shorter treatment regimens[18-21]. Moreover, alternative therapeutic regimens, such as an effective therapeutic or prophylactic vaccine for HCV infection, are being sought after and developed[22-26].

TREATMENT OF ACUTE HEPATITIS C

Diagnosis of acute HCV infection is a rare event since acutely infected individuals are mostly asymptomatic[27,28]. Also, social problems within high risk groups (especially injection drug users) keep these individuals from seeing physicians.

An optimal treatment for acute HCV infections has not been established. There are several studies showing excellent responses using IFNα[11]. The best results, with a SVR in over 95% of the patients, were achieved by using 5 million international units (MIU) of IFN daily for 4 wk, followed by 5 MIU three times weekly for another 20 wk. This treatment was well tolerated in most cases. Another recent study achieved a SVR in 87% of patients, using 6 MIU of IFN injected intramuscularly daily for 4 wk[29]. In acute HCV, genotype and RNA serum levels seem to have no influence on treatment outcomes[11,30]. While undergoing treatment, patients need to be monitored at least every four weeks for transaminases, HCV antibodies and serum RNA levels.

Since spontaneous viral clearance is documented in up to 50% of acutely infected individuals[13,30-32], some authors believe treatment should be initiated after three to four months of observation. The data to date show a worse outcome following this policy[11,13], but patients avoid the potential severe side effects of IFN therapy[33]. Also, this scheme gives an opportunity for patients with contraindications to IFN therapy; i.e. pregnancy, acute alcohol or i.v. drug abuse, and psychiatric diseases such as severe depression, to resolve these problems before starting therapy[14,17,34]. Nevertheless, delaying therapy for acute HCV infection beyond three months after onset of the disease cannot be recommended since one study showed this resulted in a dramatic drop of SVR rates (from 87% to 53%)[29]. Even if IFN monotherapy is sufficient for the therapy of acute HCV infection[35], preliminary data suggest PEG-IFN to be as effective as the IFN regime used in the reported German trial[35]. Recently, Wiegand et al[12] published a trial using PEG-IFN alpha-2b 1.5 μg per kg body weight with patients that had acute HCV infection. In patients adherent to therapy, a SVR of 94% after therapy and 89% after a follow up of 24 wk was achieved. In non-adherent patients (less than 80% of PEG-IFN application in 80% of scheduled treatment duration), the rates dropped to 82% and 71%, respectively. Furthermore, Kamal et al[36] presented a study demonstrating a combination therapy of PEG-IFN and ribavirin to be more effective than PEG-IFN monotherapy (increase of SVR from 80% with monotherapy to 85% with combination therapy). In addition, it was shown that the time point to start treatment after onset of disease is very important. A recent trial demonstrated that overall SVR dropped from 95% to 92% and then to 76% when treatment was started 8, 12 or 20 wk after onset of disease[37], respectively. Considering these data, we suggest treating acute HCV infection for 24 wk, starting immediately or at three months after onset of the disease, using a combination of PEG-INF and ribavirin in a dosage recommended for treatment of chronic HCV infection (see below).

TREATMENT OF CHRONIC HEPATITIS C

The primary treatment goal for chronic HCV infection is, as mentioned previously, sustained virologic response (SVR)[38,39]. With the recommended treatment, SVR can be achieved in about 55% of patients who are chronically infected with genotype 1 of HCV, while with genotype 2 and 3 the efficacy is 80% or greater[15,16,40]. The standard therapy is PEG-IFN alpha-2a or PEG-IFN alpha-2b subcutaneously in combination with twice daily oral doses of ribavirin[15,16,41]. The combination has proven to be more efficient than monotherapy alone, even though the antiviral mechanism of ribavirin is not fully understood[42]. Ribavirin monotherapy has no therapeutic effect in HCV infected patients[43,44].

There are two widely accepted regimens that can be followed, with both showing comparable SVR rates. Published in 2001 by Manns et al[15], PEG-IFN alpha-2b in a dose of 1.5 μg per kg body weight once a week subcutaneously plus oral ribavirin 800 mg daily led to a virus clearance of 54%. Higher ribavirin doses resulted in a lower efficacy. While genotype 1 must be treated for 48 wk to achieve the best results, treatment longer than 24 wk for genotype 2 and 3 did not raise SVR rates beyond 82%. A trial by Fried et al[16] using PEG-IFN alpha-2a demonstrated comparable results. Using PEG-IFN alpha-2a in a dose of 180 μg once a week subcutaneously plus 1000-1200 mg (depending on body weight, cut-off 75 kg) of oral ribavirin daily resulted in 56% of SVR in genotype 1 carriers, and 80% in genotype 2 and 3 carriers. Patients with genotype 1 were treated for 48 wk. In patients infected with genotype 2 and 3, a treatment period of 24 wk seemed to be sufficient. Recently, two studies have shown that treatment can be abbreviated in patients with low baseline levels of HCV-RNA (< 600 000 IU/mL) who become HCV-RNA negative. Treatment of genotype 2 and 3 for only 12 or 16 wk may be sufficient for a special population[45,46]. Therefore, therapy for HCV infection is becoming an individualized therapy.

In summary, for patients who are chronically infected with HCV, the recommendation is to use PEG-IFN alpha-2b 1.5 μg/kg per week or PEG-IFN alpha-2a 180 μg/wk plus ribavirin 1000-1200 mg/d (body weight dependent) for 48 wk for patients with genotype 1 or 24 wk for patients with genotype 2 or 3. For genotypes 4, 5 and 6, the data are not sufficient for the development of a guideline, but it has been suggested to treat patients with these genotypes in a similar way as for patients with genotype 1[47,48]. Recently, Hadziyannis et al[40] presented a study on 36 genotype 4 carriers. While patients in the short-term group (24 wk) had a SVR of 63%-67%, treatment for 48 wk resulted in a SVR of 82.

Induction therapy does not result in higher SVR rates, therefore a recommendation regarding induction therapy cannot be given[49,50], but there are ongoing individual trials.

While it is recommended to treat patients with relapse of HCV or non-responders after IFN alpha monotherapy with the described combination of PEG-IFN and ribavirin[51-54], the treatment indication for non-responders or patients with relapse after treatment with PEG-IFN alpha and ribavirin is controversial. Recent studies do not offer a general recommendation. Controlled trials to answer this question are ongoing.

During therapy, monthly monitoring of side effects, blood count, transaminases, creatinine, urea and glucose should be made. For the first 2 mo of therapy, blood counts should be made every 2 wk. Thyroid function should be considered in 12 wk intervals by measuring thyroid stimulating hormone (TSH). To monitor treatment efficacy, HCV-RNA should be determined quantitatively before and 12 wk after the start of therapy. If the RNA level drops less than 2 logs-known as early virologic response (EVR)-or remains detectable at wk 24, a successful treatment is extremely unlikely and therapy should be stopped[15,16,55-58]. The same is true if after 24 wk HCV-RNA is still measurable[59].

As mentioned above, successful treatment is defined as SVR and undetectable HCV-RNA 6 mo after the end of therapy. A recently described predictive factor is the rapid virologic response (RVR), defined as undetectable HCV RNA levels at wk 4 after the start of treatment. For patients who have genotype 1 with a low baseline viral load (< 600 000 IU/mL) and who have achieved RVR under therapy with continuous undetectable HCV-RNA afterwards, a treatment course of 24 wk may be required to match comparable results to the standard treatment of 48 wk[60]. For patients with genotype 2 or 3 and a RVR followed by undetectable RNA levels, therapy for 16 or even 12 wk may be sufficient[46]. However, reducing treatment duration in these patient populations remains controversial[61]. Therapy to increase SVR and reduce side-effects for chronic HCV infected patients is becoming more often designed for the individual, with genotype, EVR, RVR and the HCV-RNA level before start of treatment as predictors for achieving a SVR.

TREATMENT OF HEPATITIS C INFECTION IN CHILDREN

Children suffering from chronic HCV infection generally show no symptoms. While biochemistry and histology are comparable to adults with HCV, the progression of hepatitis C seems to be slower compared to adults[62-64]. It has been shown that, in general, children tolerate IFN therapy relatively well. Side effects are usually mild or moderate. One study of 41 children receiving standard combination therapy showed an overall SVR of 61% one year after treatment[65]. Altogether response rates in children to INF monotherapy and combination therapy with INF and ribavirin seem to be equivalent to adults[14,64,66,67], PEG-IFN is not yet approved for use in children. Therefore, the present regime is 15 mg ribavirin per kg body weight per day plus 3 MIU/m2 body surface interferon alpha-2b three times per week[68]. This treatment appears to be reasonably safe and effective in children with hepatitis C. Prospective controlled trials evaluating combination therapy with PEG-INF are being developed.

SIDE-EFFECTS AND CONTRAINDICATIONS FOR TREATMENT OF HEPATITIS C INFECTION

Should everybody with chronic HCV infection be treated Patients with signs of hepatitis, such as elevated transaminases (serum alanine aminotransferase level, ALT), and beginning fibrosis in liver biopsy are thought to be the most appropriate group to undergo therapy[14,69]. Nevertheless, patients with normal transaminases have the same outcome as individuals with elevated ALT[70].

People without the necessary motivation and compliance to therapy should be considered as untreated. Costs of treatment and severe side-effects must be weighed against the low efficacy of therapy in this group[14,34,71,72].

There are some absolute and relative medical contraindications for treatment with IFN, PEG-IFN and/or ribavirin. Since ribavirin is teratogenic, in both males and females, anticonception is recommended during therapy and at least 6 mo after end of therapy[73]. Also breast feeding should be avoided. People with cardiac problems rarely develop reversible arrhythmia[74] or cardiomyopathy[75] under interferon therapy. But for patients with significant cardiac disease, death from cardiac failure is more likely than from chronic hepatitis C. Therefore, within this patient group anti-viral therapy can be dispensed.

Further contraindications for treatment with interferon and/or ribavirin are hepatic decompensation and renal failure. Interferon and ribavirin can enhance liver failure[76] and, as mentioned above, close monitoring is required. Some hepatic comorbidities, additional to chronic HCV infection, are discussed later. Ribavirin undergoes renal elimination. Therefore, renal impairment leads to elevated serum levels of ribavirin, enhancing side-effects such as hemolysis. The same is true for INF, while PEG-IFN, due to its molecular size, is better tolerated in patients with end stage renal disease. PEG-IFN alpha-2a does not result in elevated serum levels even with creatinine clearance < 30 mL/min. Since kidney diseases often do not limit life expectancy, antiviral therapy must be considered in patients with both chronic HCV and end-stage renal disorder[77,78]. Available data suggests higher SVR rates in patients with renal disease, using IFN monotherapy, compared to patients with normal renal function[79,80]. Few studies have dealt with very low dose ribavirin application in these patients[81,82], alone or in combination with PEG-INF. PEG-INF α-2a should be reduced from 180 μg to 135 μg, while the recommendation for PEG-INFα-2b is dose reduction by 50%[83].

The immune system is heavily influenced by both ribavirin and interferon and this is the probable mechanism of their antiviral activity. But in HCV patients with comorbid autoimmune disease, both drugs could worsen the disease. Therefore, application of antiviral therapy must be considered dangerous as long as the autoimmune disease is not controlled.

The most common side effects of treatment with PEG-IFN are fatigue, muscle aches and psychological disorders such as depression, irritability, anxiety and sleep disturbance. Interferon further induces pancytopenia through its bone marrow depressing activity[15,16,84]. The most common adverse effect of ribavirin is haemolysis and anaemia. Therefore, patients treated with the combination therapy suffer from anaemia, with the lowest haemoglobin 4 wk after initiation of treatment[84]. Patients with ischaemic problems should be monitored closely and, if necessary, should have blood components transfused. The application of growth factors, such as erythropoetin, G-CSF or GM-CSF, cannot generally be recommended considering the cost-benefit-ratio, but growth factors may be useful in some patient populations. Significantly higher risk for bacterial infection has not been demonstrated during treatment with ribavirin and/or PEG-IFN[15,16,85,86]. The most common autoimmune reaction to therapy is the development of autoimmune thyroiditis[15,16,84,85,87]. Flu symptoms caused by interferon can be treated with paracetamol or similar drugs[84], and thyroid disorders by hormone application. More severe side effects are mood changes and depression[15,16,84,88]. The later is especially true in people already suffering from instable psychiatric disorders prior to therapy. Mild symptoms can be covered by selective serotonin reuptake inhibitors (SSRI)[89], while development of severe depression or suicidal tendencies are clear indications to discontinue therapy.

Rare side-effects are hearing impairment, hair thinning and loss, insomnia, visual disorders, interstitial pneumonia, pancreatitis, colitis and exacerbation of inflammatory diseases[83,84]. Every patient should be informed sufficiently about potential adverse events before therapy is started.

TREATMENT OF HEPATITIS C IN PATIENTS WITH LIVER CIRRHOSIS

Mortality from hepatitis C is mainly due to manifest cirrhosis. Liver biopsy studies indicate that hepatic fibrosis may regress under therapy with PEG-IFN and ribavirin[90,91]. The recommendation today is to treat patients with compensated cirrhosis with the standard combination therapy[92,93]. While patients with Child-Pugh A and B cirrhosis respond and tolerate this therapy relatively well[15,16,40,87,94], it is unclear whether a drug reduction in Child C cirrhosis should be recommended[95-97]. In general, antiviral therapy in decompensated liver cirrhosis is not recommended[98].

There is data indicating that reduction of body weight in obese patients is associated with reduction in hepatic fat[99,100] and in some cases of fibrosis[101], resulting in a better response to antiviral treatment.

A study carried out on a Japanese population demonstrated the prevention of hepatocellular carcinoma (HCC) in individuals receiving antiviral therapy[102]. The same effect may be found in Caucasians[103,104]. Successful antiviral therapy also reduces the rate of hepatic decompensation.

Overall, even if liver transplantation in end-stage disease is not prevented by antiviral therapy, the data suggest that recurrence of disease after transplantation is significantly lowered if treated previously[76].

TREATMENT OF HEPATITIS C IN PATIENTS AFTER LIVER TRANSPLANTATION

Chronic HCV infection with end-stage liver disease or hepatocellular carcinoma due to HCV is currently the most common indication for liver transplantation[105,106]. All transplanted patients become reinfected with HCV[107-111] and, combined with immune suppressive therapy to avoid rejection of the organ, some patients develop rapid progressive hepatitis[109,112-115]. In addition, acute rejection seems more frequent in patients with liver transplantation for hepatitis C[116,117].

Before transplantation, the patient should be treated for HCV infection, if possible (see above)[96,97,118]. Unfortunately, most patients in need of transplantation have decompensated disease, limiting effective antiviral therapy before transplantation[76]. Even when IFN combined with ribavirin was previously used[119-121], after transplantation the standard treatment should be PEG-IFN and ribavirin[122-128]. Nevertheless, SVR rates post-transplantation were significantly worse compared to antiviral treatment in the non-transplantation setting. Overall, SVR rates post-transplantation are only about 20%[119,123,127,129-131]. Furthermore, in a high percentage of patients, interferon and ribavirin are poorly tolerated after liver transplantation and therapy must be considered carefully[83,131].

TREATMENT OF HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV

There is a high rate of patients co-infected with HCV and HIV due to the same transmission route in high-risk populations. An estimated 25%-30% of patients with HIV are co-infected with HCV in Europe and the United States[132]. In these patients, HCV progression to end-stage liver disease is almost doubled[133,134]. Therefore, it is favourable to treat these patients as early as possible, if they have no other contraindications.

Since therapy for HCV does not significantly increase HIV RNA levels, it is recommended to use standard treatment with PEG-IFN and ribavirin. SVR rates in co-infected patients are slightly lower than in the mono-infected population[135,136]. For genotype 1 (and 4), SVR ranges from 14% to 29%, while for genotype 2 and 3 it ranges from 44% to 73%[137-139]. Patients on antiretroviral therapy are more likely to develop the side-effects of ribavirin[139-141]. These patients must be monitored closely and, in the case of severe side effects, ribavirin should be reduced or discontinued.

If HIV infection itself is not stable (CD4 count < 200 cells/mm), highly active antiretroviral therapy (HAART) should be initiated first and secondarily, after stabilisation, treatment for HCV should be started[142-144].

NEW THERAPEUTIC IDEAS FOR PATIENTS INFECTED WITH HEPATITIS C

Since the number of non-responders or patients with relapse is increasing, many new drugs are being tested briefly. Meta-analysis of several controlled trials for amantadin, for example, showed a significantly better SVR with amantadin and IFN alpha compared to IFN alpha monotherapy[19,20,145]. Further, a German study showed an increase of SVR using a triple therapy of INF alpha plus ribavirin plus amantadin compared to INF alpha plus ribavirin plus placebo[18]. Still missing are trials with PEG-INF, ribavirin and amantadin, as well as studies looking at long-term outcomes.

Further, alternative interferon types and ribavirin analogues, for example viramidine, which is a ribavirin prodrug cleaved to ribavirin in the liver, were tested to reduce side effects and were found to vary in success[146-148]. Most promising are specific inhibitors, such as specific HCV protease and HCV polymerase inhibitors, which were tested in experimental settings or phase 1-2 studies currently[21,26]. In phase 1 and 2 trials, several HCV specific protease inhibitors, such as BILN 2061, VX 950, SCH 503034, demonstrated a reduction of HCV RNA levels from 2 to 4.4 log10 from baseline[149-153]. Due to cardiac toxicity, further development of BILN 2061 has been stopped. VX 950, which is another protease inhibitor, significantly lowers HCV-RNA levels more than 4 log10 units within the first 14 d[154]. Unfortunately, in the follow-up, the concentration increased again, probably due to mutational resistance. Nevertheless, since RVR is a strong positive predictive factor, a combination of standard therapy together with VX 950 could increase SVR rates. Similar results are true for SCH 503 034 with a HCV-RNA drop of 2 to 3 log10 units. Also, specific polymerase inhibitors and nucleosid analogues have been tested for reduction of HCV RNA levels[155,156]. They result in a reduction of HCV-RNA concentrations, but they seem to be less effective in their antiviral activity than protease inhibitors[157]. Studies combining polymerase inhibitors with standard therapy are ongoing and it is most likely that polymerase and protease inhibitors will be combined with PEG-IFN in the future.

Additional concepts are the use of toll-like receptor agonists and RNA-based therapy[26], as well as drugs like thymosin-α, inosinmonophaphatedehydrogenase inhibitors, anti oxidants, glucosidase inhibitors, cytokines, inhibitors of the internal ribosomal entry site (IRES) and fusion proteins. Silymarin, which in some cases resulted in a drop of the transaminases, does not produce an effect on HCV-RNA concentration and liver histology in the trials presented to date. Most eagerly, many approaches involve a search to find a vaccine to prevent HCV infection[24,25,158].

ACKNOWLEDGMENTS

We gratefully thank Kerstin Stein, MD and Christoph Eisenbach, MD of our department for proof reading and critical comments on the manuscript.

Footnotes

S- Editor Liu Y L- Editor Lutze M E- Editor Che YB

References
1.  Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999;31 Suppl 1:88-91.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 158]  [Cited by in F6Publishing: 172]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
2.  Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology. 2000;31:756-762.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 152]  [Cited by in F6Publishing: 153]  [Article Influence: 6.4]  [Reference Citation Analysis (0)]
3.  Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 425]  [Cited by in F6Publishing: 440]  [Article Influence: 15.7]  [Reference Citation Analysis (0)]
4.  Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000;31:751-755.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 264]  [Cited by in F6Publishing: 272]  [Article Influence: 11.3]  [Reference Citation Analysis (0)]
5.  Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore). 2001;80:134-151.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 101]  [Cited by in F6Publishing: 103]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
6.  Akahane Y, Kojima M, Sugai Y, Sakamoto M, Miyazaki Y, Tanaka T, Tsuda F, Mishiro S, Okamoto H, Miyakawa Y. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med. 1994;120:748-752.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 108]  [Cited by in F6Publishing: 109]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
7.  Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-1233.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 658]  [Cited by in F6Publishing: 635]  [Article Influence: 25.4]  [Reference Citation Analysis (0)]
8.  Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31:1014-1018.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 187]  [Cited by in F6Publishing: 196]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
9.  Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodés J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21:639-644.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 119]  [Cited by in F6Publishing: 113]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
10.  Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1934]  [Cited by in F6Publishing: 1892]  [Article Influence: 75.7]  [Reference Citation Analysis (0)]
11.  Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452-1457.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 552]  [Cited by in F6Publishing: 577]  [Article Influence: 25.1]  [Reference Citation Analysis (0)]
12.  Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250-256.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 176]  [Cited by in F6Publishing: 182]  [Article Influence: 10.1]  [Reference Citation Analysis (0)]
13.  Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 357]  [Cited by in F6Publishing: 386]  [Article Influence: 18.4]  [Reference Citation Analysis (0)]
14.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002 Hepatology. 2002;36:S3-S20.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4736]  [Cited by in F6Publishing: 4513]  [Article Influence: 196.2]  [Reference Citation Analysis (0)]
16.  Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4847]  [Cited by in F6Publishing: 4695]  [Article Influence: 213.4]  [Reference Citation Analysis (0)]
17.  Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1283]  [Cited by in F6Publishing: 1348]  [Article Influence: 67.4]  [Reference Citation Analysis (0)]
18.  Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology. 2003;37:1359-1367.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 53]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
19.  Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology. 2000;32:630-634.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 88]  [Cited by in F6Publishing: 90]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
20.  Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, Ramadori G, Arnold R, Weidenbach H, Musch E. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol. 2003;39:606-613.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 31]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
21.  De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005;436:953-960.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 331]  [Cited by in F6Publishing: 316]  [Article Influence: 16.6]  [Reference Citation Analysis (0)]
22.  Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology. 2004;39:554-567.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 50]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
23.  Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939-945.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 469]  [Cited by in F6Publishing: 443]  [Article Influence: 23.3]  [Reference Citation Analysis (0)]
24.  Arvin AM, Greenberg HB. New viral vaccines. Virology. 2006;344:240-249.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 35]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
25.  Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-966.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 241]  [Cited by in F6Publishing: 252]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
26.  McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol. 2006;44:411-421.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 63]  [Cited by in F6Publishing: 65]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
27.  Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33:321-327.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 144]  [Cited by in F6Publishing: 153]  [Article Influence: 6.7]  [Reference Citation Analysis (0)]
28.  Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 556]  [Cited by in F6Publishing: 538]  [Article Influence: 23.4]  [Reference Citation Analysis (0)]
29.  Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwagi S. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213-1219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 125]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
30.  Alberti A, Boccato S, Vario A, Benvegnù L. Therapy of acute hepatitis C. Hepatology. 2002;36:S195-S200.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
31.  Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60-64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 135]  [Cited by in F6Publishing: 145]  [Article Influence: 6.9]  [Reference Citation Analysis (0)]
32.  Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology. 2003;125:597-604.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 15]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
33.  Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 344]  [Cited by in F6Publishing: 362]  [Article Influence: 12.9]  [Reference Citation Analysis (0)]
34.  Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36:S220-S225.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 57]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
35.  Wedemeyer H, Jäckel E, Wiegand J, Cornberg M, Manns MP. Whom When How Another piece of evidence for early treatment of acute hepatitis C. Hepatology. 2004;39:1201-1203.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 31]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
36.  Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721-1731.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 121]  [Cited by in F6Publishing: 125]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
37.  Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632-638.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 153]  [Cited by in F6Publishing: 162]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
38.  Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875-881.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 430]  [Cited by in F6Publishing: 423]  [Article Influence: 15.7]  [Reference Citation Analysis (0)]
39.  McHutchison JG, Davis GL, Esteban-Mur R. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon-2b alone or in combination with ribavirin. Hepatology. 2001;34:244A.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2216]  [Cited by in F6Publishing: 2085]  [Article Influence: 104.3]  [Reference Citation Analysis (0)]
41.  Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444-2451.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 361]  [Cited by in F6Publishing: 351]  [Article Influence: 19.5]  [Reference Citation Analysis (0)]
42.  Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002-1009.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 254]  [Cited by in F6Publishing: 244]  [Article Influence: 11.1]  [Reference Citation Analysis (0)]
43.  Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:897-903.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 257]  [Cited by in F6Publishing: 260]  [Article Influence: 9.0]  [Reference Citation Analysis (0)]
44.  Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26:473-477.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 278]  [Cited by in F6Publishing: 259]  [Article Influence: 9.6]  [Reference Citation Analysis (0)]
45.  von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522-527.  [PubMed]  [DOI]  [Cited in This Article: ]
46.  Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-2617.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 488]  [Cited by in F6Publishing: 509]  [Article Influence: 26.8]  [Reference Citation Analysis (0)]
47.  Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2003;63:701-730.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 40]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
48.  Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 61]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
49.  Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26:83S-88S.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 171]  [Cited by in F6Publishing: 178]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
50.  Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930-936.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 91]  [Cited by in F6Publishing: 86]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
51.  Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 927]  [Cited by in F6Publishing: 896]  [Article Influence: 34.5]  [Reference Citation Analysis (0)]
52.  Cammà C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut. 2002;51:864-869.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 19]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
53.  Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology. 2001;33:231-240.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 78]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
54.  Shiffman ML. Management of interferon therapy nonresponders. Clin Liver Dis. 2001;5:1025-1043.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 10]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
55.  Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 2001;120:1438-1447.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 203]  [Cited by in F6Publishing: 197]  [Article Influence: 8.6]  [Reference Citation Analysis (0)]
56.  Zeuzem S, Lee JH, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology. 1998;27:1149-1156.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 123]  [Cited by in F6Publishing: 128]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
57.  Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 596]  [Cited by in F6Publishing: 568]  [Article Influence: 27.0]  [Reference Citation Analysis (0)]
58.  Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36:S145-S151.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 66]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
59.  Wong JB, Davis GL, McHutchinson JG. Clinical implications of testing viral response during ribavirin and peginterferon alfa-2b treatment for chronic hepatitis C. Hepatology. 2002;36:281A.  [PubMed]  [DOI]  [Cited in This Article: ]
60.  Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 356]  [Cited by in F6Publishing: 364]  [Article Influence: 20.2]  [Reference Citation Analysis (0)]
61.  Shiffman ML, Pappas SC, Bacon B, Godofsky E, Nelson D, Harley H, Diago M, Lin A, Hooper G, Zeuzem S. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with PEGInterferon alfa-2A (40KD) plus ribavirin: findings from accelerate. Hepatology. 2006;44:97A340.  [PubMed]  [DOI]  [Cited in This Article: ]
62.  Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866-870.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 358]  [Cited by in F6Publishing: 374]  [Article Influence: 15.0]  [Reference Citation Analysis (0)]
63.  Jacobson IM, Ahmed F, Russo MW, Brown RS, Lebovics E, Min A, Esposito S, Brau N, Tobias H, Klion F. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therpay relapsers: final results (abstr). Gastroenterology. 2003;124 Suppl 1:A714.  [PubMed]  [DOI]  [Cited in This Article: ]
64.  Jonas MM. Children with hepatitis C. Hepatology. 2002;36:S173-S178.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 50]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
65.  Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002;36:1280-1284.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 90]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
66.  Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol. 2003;38 Suppl 1:S104-S118.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 89]  [Cited by in F6Publishing: 92]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
67.  Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2002;34:52-58.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 87]  [Cited by in F6Publishing: 87]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
68.  González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005;42:1010-1018.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 103]  [Cited by in F6Publishing: 112]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
69.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol. 1999;31 Suppl 1:3-8.  [PubMed]  [DOI]  [Cited in This Article: ]
70.  Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-1732.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 178]  [Cited by in F6Publishing: 184]  [Article Influence: 9.2]  [Reference Citation Analysis (0)]
71.  Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36:S210-S219.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 57]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
72.  Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users. N Engl J Med. 2001;345:211-215.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 158]  [Cited by in F6Publishing: 168]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
73.  Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat. 2005;12:223-235.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 57]  [Cited by in F6Publishing: 53]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
74.  Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, Masur H, Fauci AS, Lane HC. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med. 1989;321:1246-1249.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 93]  [Cited by in F6Publishing: 96]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
75.  Angulo MP, Navajas A, Galdeano JM, Astigarraga I, Fernández-Teijeiro A. Reversible cardiomyopathy secondary to alpha-interferon in an infant. Pediatr Cardiol. 1999;20:293-294.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 14]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
76.  Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389-396.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 234]  [Cited by in F6Publishing: 238]  [Article Influence: 11.3]  [Reference Citation Analysis (0)]
77.  Gentil MA, Rocha JL, Rodríguez-Algarra G, Pereira P, López R, Bernal G, Muñoz J, Naranjo M, Mateos J. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant. 1999;14:2455-2460.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 88]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
78.  Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226-S236.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 24]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
79.  Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610-1615.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 130]  [Cited by in F6Publishing: 138]  [Article Influence: 6.6]  [Reference Citation Analysis (0)]
80.  Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 269]  [Cited by in F6Publishing: 280]  [Article Influence: 12.7]  [Reference Citation Analysis (0)]
81.  Bruchfeld A, Lindahl K, Ståhle L, Söderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18:1573-1580.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 115]  [Cited by in F6Publishing: 128]  [Article Influence: 6.1]  [Reference Citation Analysis (0)]
82.  Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42:1109-1115.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 64]  [Cited by in F6Publishing: 69]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
83.  Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 276]  [Cited by in F6Publishing: 267]  [Article Influence: 14.8]  [Reference Citation Analysis (0)]
84.  Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-S244.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 331]  [Cited by in F6Publishing: 295]  [Article Influence: 13.4]  [Reference Citation Analysis (0)]
85.  Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 197]  [Cited by in F6Publishing: 192]  [Article Influence: 9.1]  [Reference Citation Analysis (0)]
86.  Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, Hoofnagle JH. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-1279.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 160]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
87.  McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2509]  [Cited by in F6Publishing: 2417]  [Article Influence: 93.0]  [Reference Citation Analysis (0)]
88.  Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 883]  [Cited by in F6Publishing: 933]  [Article Influence: 38.9]  [Reference Citation Analysis (0)]
89.  Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 788]  [Cited by in F6Publishing: 704]  [Article Influence: 30.6]  [Reference Citation Analysis (0)]
90.  Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 828]  [Cited by in F6Publishing: 779]  [Article Influence: 35.4]  [Reference Citation Analysis (0)]
91.  Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol. 2004;2:183-197.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 15]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
92.  Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36:S185-S194.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 38]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
93.  Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology. 1999;117:408-413.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 108]  [Cited by in F6Publishing: 113]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
94.  Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 657]  [Cited by in F6Publishing: 668]  [Article Influence: 27.8]  [Reference Citation Analysis (0)]
95.  Everson GT. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol. Hepatology. 2002;36:297A.  [PubMed]  [DOI]  [Cited in This Article: ]
96.  Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl. 2003;9:S90-S94.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 53]  [Cited by in F6Publishing: 50]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
97.  Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255-262.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 292]  [Cited by in F6Publishing: 300]  [Article Influence: 15.8]  [Reference Citation Analysis (0)]
98.  Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 269]  [Cited by in F6Publishing: 273]  [Article Influence: 12.4]  [Reference Citation Analysis (0)]
99.  Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 446]  [Cited by in F6Publishing: 422]  [Article Influence: 20.1]  [Reference Citation Analysis (0)]
100.  Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38:639-644.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 268]  [Cited by in F6Publishing: 266]  [Article Influence: 12.7]  [Reference Citation Analysis (0)]
101.  Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89-94.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 201]  [Cited by in F6Publishing: 215]  [Article Influence: 9.8]  [Reference Citation Analysis (0)]
102.  Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-181.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 833]  [Cited by in F6Publishing: 760]  [Article Influence: 30.4]  [Reference Citation Analysis (0)]
103.  Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593-602.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 277]  [Cited by in F6Publishing: 294]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
104.  Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001;15:689-698.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 98]  [Cited by in F6Publishing: 102]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
105.  Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998;17-37.  [PubMed]  [DOI]  [Cited in This Article: ]
106.  Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436:973-978.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 269]  [Cited by in F6Publishing: 277]  [Article Influence: 14.6]  [Reference Citation Analysis (0)]
107.  Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 888]  [Cited by in F6Publishing: 822]  [Article Influence: 37.4]  [Reference Citation Analysis (0)]
108.  Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkholt L. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999;117:619-625.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 284]  [Cited by in F6Publishing: 289]  [Article Influence: 11.6]  [Reference Citation Analysis (0)]
109.  Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830-836.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 289]  [Cited by in F6Publishing: 257]  [Article Influence: 12.9]  [Reference Citation Analysis (0)]
110.  Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001;1:197-203.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 66]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
111.  Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14-S18.  [PubMed]  [DOI]  [Cited in This Article: ]
112.  Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11:386-395.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 78]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
113.  Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202-210.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 515]  [Cited by in F6Publishing: 525]  [Article Influence: 23.9]  [Reference Citation Analysis (0)]
114.  Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant. 2005;5:549-557.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 139]  [Cited by in F6Publishing: 129]  [Article Influence: 6.8]  [Reference Citation Analysis (0)]
115.  Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl. 2002;8:S19-S27.  [PubMed]  [DOI]  [Cited in This Article: ]
116.  McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl. 2004;10:975-985.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 41]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
117.  Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250-256.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 450]  [Cited by in F6Publishing: 410]  [Article Influence: 16.4]  [Reference Citation Analysis (0)]
118.  Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003;9:905-915.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 117]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
119.  Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003;124:642-650.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 284]  [Cited by in F6Publishing: 289]  [Article Influence: 13.8]  [Reference Citation Analysis (0)]
120.  Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, Ottobrelli A, Zamboni F, Fadda M, Bobbio A. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 2002;37:247-252.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 98]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
121.  Berenguer M, Prieto M, Palau A, Carrasco D, Rayón JM, Calvo F, Berenguer J. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol. 2004;16:1207-1212.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 25]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
122.  Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc. 2003;35:3042-3044.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 50]  [Cited by in F6Publishing: 53]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
123.  Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289-298.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 229]  [Cited by in F6Publishing: 235]  [Article Influence: 12.4]  [Reference Citation Analysis (0)]
124.  Bahr MJ, Manns MP. Changing faces-natural course and treatment of hepatitis C after liver transplantation. J Hepatol. 2004;40:699-701.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 9]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
125.  Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 2004;40:669-674.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 184]  [Cited by in F6Publishing: 187]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
126.  Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2004;41:2-10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 31]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
127.  Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004;77:190-194.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 149]  [Cited by in F6Publishing: 136]  [Article Influence: 6.8]  [Reference Citation Analysis (0)]
128.  Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005;5:118-124.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 156]  [Cited by in F6Publishing: 145]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
129.  Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, Williams R. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology. 1998;27:1403-1407.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 125]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
130.  Sheiner PA. Hepatitis C after liver transplantation. Semin Liver Dis. 2000;20:201-209.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 19]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
131.  Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002;8:S28-S37.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 43]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
132.  Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 546]  [Cited by in F6Publishing: 570]  [Article Influence: 25.9]  [Reference Citation Analysis (0)]
133.  Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002;100:1584-1589.  [PubMed]  [DOI]  [Cited in This Article: ]
134.  Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283-287.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 310]  [Cited by in F6Publishing: 314]  [Article Influence: 13.7]  [Reference Citation Analysis (0)]
135.  Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002;36:S201-S209.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 49]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
136.  Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas JR, Pedreira J, Barreiro P, García-Samaniego J, Martín-Carbonero L. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 160]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
137.  Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 716]  [Cited by in F6Publishing: 679]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
138.  Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 992]  [Cited by in F6Publishing: 946]  [Article Influence: 47.3]  [Reference Citation Analysis (0)]
139.  Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 652]  [Cited by in F6Publishing: 618]  [Article Influence: 30.9]  [Reference Citation Analysis (0)]
140.  Bräu N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, Frost KR, Kostman JR. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39:989-998.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 61]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
141.  Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-281.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 235]  [Cited by in F6Publishing: 238]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
142.  Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 396]  [Cited by in F6Publishing: 422]  [Article Influence: 20.1]  [Reference Citation Analysis (0)]
143.  Kottilil S, Polis MA, Kovacs JA. HIV Infection, hepatitis C infection, and HAART: hard clinical choices. JAMA. 2004;292:243-250.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 21]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
144.  Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002;16:1915-1923.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 118]  [Cited by in F6Publishing: 121]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
145.  Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR, Zeuzem S, Berg T. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol. 2004;40:478-483.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 27]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
146.  Nelson D, Rustgi V, Balan V, McHutchinson JG, Davis GL, Lambiase L. A phase 2 study of albuferon in combination with ribavirin in nonresponders to prior interferon therapy for chronic hepatitis C. Hepatology. 2005;42:278A.  [PubMed]  [DOI]  [Cited in This Article: ]
147.  Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother. 2003;47:426-431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 48]  [Cited by in F6Publishing: 51]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
148.  Gish RG, Nelson D, Arora S, Fried MW, Reddy KR, Xu Y. Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alfa-2a. J Hepatol. 2005;42:39A.  [PubMed]  [DOI]  [Cited in This Article: ]
149.  Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186-189.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 716]  [Cited by in F6Publishing: 654]  [Article Influence: 31.1]  [Reference Citation Analysis (0)]
150.  Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004;127:1347-1355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 262]  [Cited by in F6Publishing: 268]  [Article Influence: 13.4]  [Reference Citation Analysis (0)]
151.  Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005;41:832-835.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 139]  [Cited by in F6Publishing: 144]  [Article Influence: 7.6]  [Reference Citation Analysis (0)]
152.  Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J. Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology. 2005;42:234A.  [PubMed]  [DOI]  [Cited in This Article: ]
153.  Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-INF-a). Hepatology. 2005;42:233A.  [PubMed]  [DOI]  [Cited in This Article: ]
154.  Kieffer T, Sarrazin C, Miller J, Traver S, Zhou Y, Bartels D, Hanzelka B, Müh U, Lin C, Reesink HW. Combination of Telaprevir (VX-950) and PEG-IFN-ALFA suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1B study. Hepatology. 2006;44:222A92.  [PubMed]  [DOI]  [Cited in This Article: ]
155.  Afdahl N, Godofsky E, Dienstag JL, Rustgi V, Schick L, McEniry D. Final phaseI/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology. 2004;40:726A.  [PubMed]  [DOI]  [Cited in This Article: ]
156.  O'Brien C, Godofsky E, Rodriguez-Torres M, Afdahl N, Pappas SC, Pockros P. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs. retreatment with peg-interferon plus ribavirin (pegINF/RBV) in hepatitis C patients with previous non-response to PegINF/RBV: first interim results. Hepatology. 2005;42:234A.  [PubMed]  [DOI]  [Cited in This Article: ]
157.  Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, McEniry D, Chasen R, Goff J. Knox S, Kleber K, Belanger B, Brown NA, Dieterich D, Valopicitabine (NM283) plus PEG-Interferon in treatment-naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology. 2006;44:223A93.  [PubMed]  [DOI]  [Cited in This Article: ]
158.  Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis. 2005;192:2112-2116.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 43]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]